Skip to Main Content

Advertisement

Skip Nav Destination

Minimal Residual Disease Monitoring By Targeted Mass Spectrometry Allows Early Relapse Detection in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 2349–2350.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement